Document is current

Article History

Received: 18 February 2025

Accepted: 23 June 2025

First Online: 7 July 2025

Declarations

:

: All experimental procedures in these studies were approved by the National Cancer Institute at Frederick and the National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Boards and performed in accordance with the relevant guidelines and regulations. Samples were obtained from 30 participants who were enrolled in following institutional review board-approved NIH studies: Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection (ClinicalTrials registration number NCT00789009), A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy (ClinicalTrials registration number NCT05612178), A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection (ClinicalTrials registration number NCT05582694) and Tissue Biopsy and Imaging Studies in HIV-Infected Patients (ClinicalTrials registration number NCT00001471). The participants provided written informed consent.

: Not applicable.

: The authors declare no competing interests.